ACCP 2024 Poster: Lorundrostat Concentration-QTc Results From the First-in-Human Study in Healthy Participants Demonstrate Lack of Relevant Effect and Replaces the Thorough QT Study September 8, 2024 5:00 PM
First-in-human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor August 26, 2024 8:38 PM
AHA Scientific Sessions 2023 Poster: Lorundrostat for Treatment of Obesity-Related, Aldosterone-Dependent Hypertension November 11, 2023 11:30 AM – An Endotype-Specific, Targeted Approach to the Treatment of Uncontrolled Hypertension
ASN Kidney Week 2023 Poster: Identification of a Hypertensive Endotype with a Median Treatment Effect of -32 mmHg in Response to the Novel Aldosterone Synthase Inhibitor Lorundrostat November 2, 2023 10:00 AM
JAMA: Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension – The Target-HTN Randomized Clinical Trial September 11, 2023 2:04 PM
JAMA Editorial: A New Dawn for Aldosterone as a Therapeutic Target in Hypertension September 10, 2023 9:07 AM
